Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 7/20 | 0.35 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | KCNJ6 | P48051 | 3/20 | 0.32 |
| ▸ | KCNJ5 | P48544 | 3/20 | 0.32 |
| ▸ | KCNJ3 | P48549 | 3/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.32 |
| ▸ | MTOR | P42345 | 5/20 | 0.32 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | RXRB | P28702 | 2/20 | 0.32 |
| ▸ | RXRG | P48443 | 2/20 | 0.32 |
| ▸ | RARA | P10276 | 1/20 | 0.32 |
| ▸ | RARB | P10826 | 1/20 | 0.32 |
| ▸ | RARG | P13631 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25270071 | 1.00 | FFAR1 (0.35) | FFAR1CYP2C8CYP2C9KCNJ6KCNJ5 | |
| SCHEMBL25589575 | 0.89 | KCNJ6 (0.34) | KCNJ6KCNJ5KCNJ3PIK3CAMTOR | |
| SCHEMBL25590349 | 0.85 | MAPT (0.35) | KCNJ6KCNJ5KCNJ3PIK3CAMTOR | |
| SCHEMBL30393922 | 0.85 | MAPT (0.35) | KCNJ6KCNJ5KCNJ3PIK3CAMTOR | |
| SCHEMBL23994571 | 0.81 | KCNJ6 (0.39) | KCNJ6KCNJ5KCNJ3PIK3CAMTOR | |
| SCHEMBL25589570 | 0.81 | RIPK1 (0.31) | — | |
| SCHEMBL30393431 | 0.81 | RIPK1 (0.31) | — | |
| SCHEMBL25590354 | 0.81 | RIPK1 (0.31) | — | |
| SCHEMBL25004868 | 0.78 | PDE10A (0.33) | MAPK1 | |
| SCHEMBL23995384 | 0.77 | CYP17A1 (0.33) | MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230183189-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. | 2023-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230183189-A1 | CD73 COMPOUNDS | ENTPD5, NT5E, ENTPD1 | FFAR1 2266/4885CYP2C8 953/4885CYP2C9 935/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.